Wednesday, May 6, 2026
Four years after Dobbs Mifepristone again on edge of ban
Certain high risk drugs are subject to REMS - risk evaluation and mitigation strategies. The abortifacient drug Mifepristone has one such drug. But the FDA - during the administration of Joe Biden rejected such a categorization, making the drug widely accessible.
In Louisiana v. FDA the 5th Circuit Court of Appeals has issued a nationwide injunction against prescription of Mifepristone, the abortifacient drug.
Subscribe to:
Posts (Atom)